2010 46th ASCO Annual Meeting - účast ČR

Adjuvant Therapy

Neoadjuvant chemotherapy AC-D in breast cancer patients

Autoři: MUDr. Olga Přibylová, PhD.; prof. MUDr. Luboš Petruželka, CSc.; prof. MUDr. Petra Tesařová, CSc.; Mgr. Adam Svobodník, Ph.D.
Číslo abstraktu: e11009
Kategorie: Zhoubné nádory prsu

CNS Tumors

A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma

Autoři: R. Stupp; A. Kanner; H. Engelhard; V. Heidecke; S. Taillibert; F. S. Lieberman; MUDr. Vladimír Dbalý, MBA; E. D. Kirson; Y. Palti; P. H. Gutin
Číslo abstraktu: LBA2007
Kategorie: zhoubné nádory mozku a CNS

Colorectal Cancer

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST)

Autoři: J. Douillard; J. Cassidy; prof. dr hab. n. med. Jacek Jassem; Fernando Rivera; doc. MUDr. Ilona Kocáková, Ph.D.; MD Wojciech Rogowski; J. R. Canon; E. P. Yanez; Xu F.; J. L. Gansert
Číslo abstraktu: 3528
Kategorie: Kolorektální karcinom

GIST

Prognostic significance of proliferation markers and telomerase activity in gastrointestinal stromal tumors

Autoři: Mgr. Alena Augustiňáková; Mgr. Helena Břízová; Bc. Irena Hilská; RNDr. Markéta Kalinová, Ph.D.; prof. MUDr. Roman Kodet, CSc.
Číslo abstraktu: 10078
Kategorie: Gastrointestinální nádory

Leukemia

Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL)

Autoři: MD William G. Wierda, PhD; MD Thomas J. Kipps, PhD; MD Jan Dürig; M.D. Laimonas Griskevicius (Griškevičius); MD Stephan Stilgenbauer; prof. MUDr. Jiří Mayer, CSc.; Michele M. Gorczyca, MS; Marc Andersen, Ph.D.; T. Nielsen; Charlotte A Russell
Číslo abstraktu: 6520
Kategorie: Maligní lymfomy a leukémie

Lymphoma

Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy

Autoři: MD Gilles Andre Salles, PhD; Prof. John Francis Seymour, MD, PhD, MBBS, FRACP; MD Pierre Feugier, PhD; MD Fritz C. Offner, PhD; MD Armando Lopez-Guillermo; MD Reda Bouabdallah; MD Lars Moller Pedersen, PhD; MD Pauline Brice; MUDr. David Belada, Ph.D.; MD Luc Xerri, PhD
Číslo abstraktu: 8004
Kategorie: Maligní lymfomy a leukémie

Relapse of Hodgkins lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT

Autoři: C. Martinez; C. Canals; MD Emilio Paolo Alessandrino; D. Karakasis; Giuseppe Leone; Prof. MUDr. Marek Trněný, CSc.; J. Snowden; Prof. Jane F. Apperley, MBChB, MD, FRCP, FRCPath; MD Noel-Jean Milpied, Ph.D.; Anna Sureda, MD
Číslo abstraktu: 8060
Kategorie: Maligní lymfomy a leukémie

Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkins lymphoma (NHL)

Autoři: MUDr. David Belada, Ph.D.; prof. MUDr. Jiří Mayer, CSc.; MD Myron Stefan Czuczman; I. W. Flinn; B. Durbin-Johnson; G. L. Bray
Číslo abstraktu: 8104
Kategorie: Maligní lymfomy a leukémie

Metastatic

A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC)

Autoři: F. H. Blackhall; Z. Márk; prof. MUDr. Petr Zatloukal (1955-2012), CSc.; B. Szima; Dr. István Albert; E. Juhász; X. Yang; D. Smethurst; Y. Hei; J. Soria
Číslo abstraktu: 7534
Kategorie: Zhoubné nádory plic a průdušek

First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology

Autoři: K. J. OByrne; J. Von Pawel; I. Vynnychenko; prof. MUDr. Petr Zatloukal (1955-2012), CSc.; F. De Marinis; W. E. Eberhardt; L. G. Paz-Ares; K. Schumacher; U. Gatzemeier; Prof., Mag., Dr. Robert Pirker
Číslo abstraktu: 7556
Kategorie: Zhoubné nádory plic a průdušek

Intravenous vinorelbine (NVBiv) on D1 and oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first-line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonselected population

Autoři: prof. MUDr. Jana Skřičková, CSc.; MUDr. Lenka Jakubíková, Ph.D.; MUDr. Marcela Tomíšková; MUDr. Bohdan Kadlec
Číslo abstraktu: e18061
Kategorie: Zhoubné nádory plic a průdušek

Metastatic Breast Cancer

Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months

Autoři: prof. MUDr. Luboš Petruželka, CSc.; V. Ganju; D. Becquart; P. F. Conte; N. Tubiana-Mathieu; M. J. Gil Gil; M. Morand; Nathalie Vaissiere; G. Villanova; A. T. C. Chan
Číslo abstraktu: 1077
Kategorie: Zhoubné nádory prsu

Factors associated with the choice of taxane monotherapy or combination in the management of advanced breast cancer: Results of an international observational study

Autoři: C. Camci; E. Firoiu; M. Gumus; F. Hurtado de Mendoza; M. A. Chavez-Zamudio; N. Davidson; MUDr. Milan Brychta; M. Donadio; V. Soldatenkova; K. A. Benhadji
Číslo abstraktu: 1132
Kategorie: Zhoubné nádory prsu

A phase III study (EMBRACE) of eribulin mesylate versus treatment of physicians choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane

Autoři: Prof. Chris Twelves; D. Loesch; J. L. Blum; L. T. Vahdat; MUDr. Katarína Petráková, Ph.D.; P. J. Chollet; MD Corina Elena Akerele; S. Seegobin; J. Wanders; M.D. Jorge E. Cortes
Číslo abstraktu: CRA1004
Kategorie: Zhoubné nádory prsu

A double-blind, randomized, placebo-controlled phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylase inhibitor (HDACi) entinostat in metastatic breast cancer (MBC)

Autoři: Denise Aysel Yardley; R. Ismail-Khan; J. F. Eakle; K. Miller; D. Paul; Dr. Virginia F. Borges, MMSc.; T. L. Helsten; J. F. Kroener; prof. MUDr. Bohuslav Melichar, Ph.D.; K. H. Tkaczuk
Číslo abstraktu: TPS128
Kategorie: Zhoubné nádory prsu

Multiple Myeloma

Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).

Autoři: Sundar Jagannath; MD David Samuel diCapua Siegel, PhD; prof. MUDr. Roman Hájek, CSc.; Meletios Athanasios Dimopoulos, MD; MD Sung-Soo Yoon, PhD; Prof. MD Sagar Lonial; MD Thorsten Graef, PhD; Lisa Lupinacci; David Reiser; MD Kenneth C. Anderson
Číslo abstraktu: 8133
Kategorie: Mnohočetný myelom

Other

In vitro activation of CMV-specific T-cell response using CyaA toxoids delivering peptide antigenic epitopes derived from pp65 protein

Autoři: RNDr. Jiří Jelínek; Irena Adkins; Peter Šebo; Prof. MUDr. Jaroslav Michálek, Ph.D.
Číslo abstraktu: 6610
Kategorie: Maligní lymfomy a leukémie

Ovarian Cancer

Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial

Autoři: P. Sabbatini; J. S. Berek; A. Casado; MUDr. Karel Cwiertka, Ph.D.; Tamas Pinter; A. Pluzanska; G. Scambia; M.D. Eric Pujade-Lauraine, Ph.D.; J. B. Vermorken; J. Pfisterer
Číslo abstraktu: 5036
Kategorie: Zhoubné gynekologické nádory

Prognostic Factors

The clinical significance of triple-negative breast cancer in men (MBC)

Autoři: R. Foerster; F. G. Foerster; V. Wulff; B. Schubotz; R. Lange; J. Habeck; D. Baaske; C. Rudlowski
Číslo abstraktu: e21011
Kategorie: Zhoubné nádory prsu